These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24128669)

  • 41. Susceptibility to antiretroviral drugs of CRF01_AE, CRF02_AG, and subtype C viruses from untreated patients of Africa and Asia: comparative genotypic and phenotypic data.
    Fleury HJ; Toni T; Lan NT; Hung PV; Deshpande A; Recordon-Pinson P; Boucher S; Lazaro E; Jauvin V; Lavignolle-Aurillac V; Lebel-Binay S; Cheret A; Masquelier B
    AIDS Res Hum Retroviruses; 2006 Apr; 22(4):357-66. PubMed ID: 16623640
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genotypic resistance profiles in antiretroviral-naive HIV-1 infections before and after initiation of first-line HAART: impact of polymorphism on resistance to therapy.
    Sukasem C; Churdboonchart V; Sukeepaisarncharoen W; Piroj W; Inwisai T; Tiensuwan M; Chantratita W
    Int J Antimicrob Agents; 2008 Mar; 31(3):277-81. PubMed ID: 18182278
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genotypic coreceptor analysis.
    Sierra S; Kaiser R; Thielen A; Lengauer T
    Eur J Med Res; 2007 Oct; 12(9):453-62. PubMed ID: 17933727
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action.
    Langley DR; Kimura SR; Sivaprakasam P; Zhou N; Dicker I; McAuliffe B; Wang T; Kadow JF; Meanwell NA; Krystal M
    Proteins; 2015 Feb; 83(2):331-50. PubMed ID: 25401969
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120.
    Ogert RA; Wojcik L; Buontempo C; Ba L; Buontempo P; Ralston R; Strizki J; Howe JA
    Virology; 2008 Apr; 373(2):387-99. PubMed ID: 18190945
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevalence of gp160 polymorphisms known to be related to decreased susceptibility to temsavir in different subtypes of HIV-1 in the Los Alamos National Laboratory HIV Sequence Database.
    Gartland M; Arnoult E; Foley BT; Lataillade M; Ackerman P; Llamoso C; Krystal M
    J Antimicrob Chemother; 2021 Oct; 76(11):2958-2964. PubMed ID: 34297843
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity.
    Garcia-Perez J; Staropoli I; Azoulay S; Heinrich JT; Cascajero A; Colin P; Lortat-Jacob H; Arenzana-Seisdedos F; Alcami J; Kellenberger E; Lagane B
    Retrovirology; 2015 Jun; 12():50. PubMed ID: 26081316
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fostemsavir: First Approval.
    Markham A
    Drugs; 2020 Sep; 80(14):1485-1490. PubMed ID: 32852743
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment 6. Preclinical and human pharmacokinetic profiling of BMS-663749, a phosphonooxymethyl prodrug of the HIV-1 attachment inhibitor 2-(4-benzoyl-1-piperazinyl)-1-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-oxoethanone (BMS-488043).
    Kadow JF; Ueda Y; Meanwell NA; Connolly TP; Wang T; Chen CP; Yeung KS; Zhu J; Bender JA; Yang Z; Parker D; Lin PF; Colonno RJ; Mathew M; Morgan D; Zheng M; Chien C; Grasela D
    J Med Chem; 2012 Mar; 55(5):2048-56. PubMed ID: 22356441
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A combination of polymorphic mutations in V3 loop of HIV-1 gp120 can confer noncompetitive resistance to maraviroc.
    Yuan Y; Maeda Y; Terasawa H; Monde K; Harada S; Yusa K
    Virology; 2011 May; 413(2):293-9. PubMed ID: 21440278
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Small Molecule HIV-1 Attachment Inhibitors: Discovery, Mode of Action and Structural Basis of Inhibition.
    Lai YT
    Viruses; 2021 May; 13(5):. PubMed ID: 34066522
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial.
    Lalezari JP; Latiff GH; Brinson C; Echevarría J; Treviño-Pérez S; Bogner JR; Thompson M; Fourie J; Sussmann Pena OA; Mendo Urbina FC; Martins M; Diaconescu IG; Stock DA; Joshi SR; Hanna GJ; Lataillade M;
    Lancet HIV; 2015 Oct; 2(10):e427-37. PubMed ID: 26423650
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
    Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
    J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Analysis of Clinical HIV-1 Strains with Resistance to Maraviroc Reveals Strain-Specific Resistance Mutations, Variable Degrees of Resistance, and Minimal Cross-Resistance to Other CCR5 Antagonists.
    Flynn JK; Ellenberg P; Duncan R; Ellett A; Zhou J; Sterjovski J; Cashin K; Borm K; Gray LR; Lewis M; Jubb B; Westby M; Lee B; Lewin SR; Churchill M; Roche M; Gorry PR
    AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1220-1235. PubMed ID: 28797170
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genotypic resistance tests for the management of the HIV-infected patient with non-B viral isolates.
    Visco-Comandini U; Balotta C
    Scand J Infect Dis Suppl; 2003; 106():75-8. PubMed ID: 15000590
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes.
    Holguín A; Ramirez de Arellano E; Rivas P; Soriano V
    AIDS Rev; 2006; 8(2):98-107. PubMed ID: 16848277
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase.
    Quashie PK; Oliviera M; Veres T; Osman N; Han YS; Hassounah S; Lie Y; Huang W; Mesplède T; Wainberg MA
    J Virol; 2015 Mar; 89(6):3163-75. PubMed ID: 25552724
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predicted genotypic resistance to the novel entry inhibitor, BMS-378806, among HIV-1 isolates of subtypes A to G.
    Moore PL; Cilliers T; Morris L
    AIDS; 2004 Nov; 18(17):2327-30. PubMed ID: 15577547
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Docking and 3D-QSAR studies of BMS-806 analogs as HIV-1 gp120 entry inhibitors.
    Teixeira C; Serradji N; Maurel F; Barbault F
    Eur J Med Chem; 2009 Sep; 44(9):3524-32. PubMed ID: 19410340
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Detection of HIV-1 CXCR4 tropism and resistance in treatment experienced subjects receiving CCR5 antagonist-Vicriviroc.
    McNicholas P; Vilchez RA; Greaves W; Kumar S; Onyebuchi C; Black T; Strizki JM
    J Clin Virol; 2012 Oct; 55(2):134-9. PubMed ID: 22824230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.